The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal Cancer
Open accessAbstract
Purpose: Neoadjuvant chemoradiotherapy for rectal cancer is associated with improved local control and may result in complete tumor response. Associations between tumor response and disease control following radical resection should be established before tumor response is used to evaluate treatment strategies. The purpose of this study was to assess and compare oncologic outcomes associated with the degree of pathologic response after chemoradiotherapy. Patients and Methods: All patients with locally advanced (cT3-4 or cN+ by endorectal ultrasonography, computed tomography, or magnetic resonance imaging) rectal carcinoma diagnosed from 1993 to 2008 at our institution and treated with preoperative chemoradiotherapy and radical resection were identified, and their records were retrospectively reviewed. The median radiation dose was 50.4 Gy with concurrent chemotherapy. Recurrence-free survival (RFS), distant metastasis (DM), and local recurrence (LR) rates were compared among patients with complete (ypT0N0), intermediate (ypT1-2N0), or poor (ypT3-4 or N+) response by using Kaplan-Meier survival analysis and multivariate Cox proportional hazards regression. Results: In all, 725 patients were classified by tumor response: complete (131; 18.1%), intermediate (210; 29.0%), and poor (384; 53.0%). Age, sex, cN stage, and tumor location were not related to tumor response. Tumor response (complete v intermediate v poor) was associated with 5-year RFS (90.5% v 78.7% v 58.5%; P < .001), 5-year DM rates (7.0% v 10.1% v 26.5%; P < .001), and 5-year LR only rates (0% v 1.4% v 4.4%; P = .002). Conclusion: Treatment response to neoadjuvant chemoradiotherapy among patients with locally advanced rectal cancer undergoing radical resection is an early surrogate marker and correlate to oncologic outcomes. These data provide guidance with response-stratified oncologic benchmarks for comparisons of novel treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
Bosset, J.-F., Collette, L., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., Daban, A., Bardet, E., Beny, A., & Ollier, J.-C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060829 · Cited by 2,688
Maas, M., Nelemans, P. J., Valentini, V., Das, P., Rödel, C., Kuo, L.-J., Calvo, F. A., García-Aguilar, J., Glynne-Jones, R., Haustermans, K., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70172-8 · Cited by 1,945
Self-citationHabr-Gama, A., Perez, R. O., Nadalin, W., Sabbaga, J., Ribeiro, U., Silva e Sousa, A. H., Campos, F. G., Kiss, D. R., & Gama-Rodrigues, J. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000141194.27992.32 · Cited by 1,893
Prognostic Significance of Tumor Regression After Preoperative Chemoradiotherapy for Rectal Cancer
Rödel, C., Martus, P., Papadoupolos, T., Füzesi, L., Klimpfinger, M., Fietkau, R., Liersch, T., Hohenberger, W., Raab, R., Sauer, R., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.1329 · Cited by 1,215
Fisher, B., Wolmark, N., Rockette, H., Redmond, C., Deutsch, M., Wickerham, D. L., Fisher, E. R., Caplan, R., Jones, J., Lerner, H., et al. (1988) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/80.1.21 · Cited by 1,030
Brunia, C. H. M., & van Boxtel, G. J. M. (2001) · International Journal of Psychophysiology · doi:10.1016/s0167-8760(01)00179-9 · Cited by 721
Washington, M. K., Berlin, J., Branton, P., Burgart, L. J., Carter, D. K., Fitzgibbons, P. L., Halling, K., Frankel, W., Jessup, J., Kakar, S., et al. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.10.1539 · Cited by 529
Collette, L., Bosset, J.-F., den Dulk, M., Nguyen, F., Mineur, L., Maingon, P., Radosevic-Jelic, L., Piérart, M., & Calais, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.9685 · Cited by 447
Capirci, C., Valentini, V., Cionini, L., De Paoli, A., Rodel, C., Glynne-Jones, R., Coco, C., Romano, M., Mantello, G., Palazzi, S., et al. (2008) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.12.019 · Cited by 445
Das, P., Skibber, J. M., Rodriguez‐Bigas, M. A., Feig, B. W., Chang, G. J., Wolff, R. A., Eng, C., Krishnan, S., Janjan, N. A., & Crane, C. H. (2007) · Cancer · doi:10.1002/cncr.22625 · Cited by 332
Self-citation
Cited by
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
A rectal cancer organoid platform to study individual responses to chemoradiation
Ganesh, K., Wu, C., O’Rourke, K. P., Szeglin, B. C., Zheng, Y., Sauvé, C.-E. G., Adileh, M., Wasserman, I., Marco, M. R., Kim, A. S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0584-2 · Cited by 569
Learning from clinical trials of neoadjuvant checkpoint blockade
Versluis, J. M., Long, G. V., & Blank, C. U. (2020) · Nature Medicine · doi:10.1038/s41591-020-0829-0 · Cited by 234
Sanoff, H. K., Moon, D. H., Moore, D. T., Boles, J., Bui, C., Blackstock, W., O'Neil, B. H., Subramaniam, S., McRee, A. J., Carlson, C., et al. (2019) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2019.02.021 · Cited by 72
Metadata
- Authors
- Park, I. J., You, Y. N., Agarwal, A., Skibber, J. M., Rodriguez-Bigas, M. A., Eng, C., Feig, B. W., Das, P., Krishnan, S., Crane, C. H., Hu, C.-Y., & Chang, G. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2012-05-20
- Volume
- 30
- Issue
- 15
- Pages
- 1770-1776
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2118983280
- Cited by
- 485
- References
- 20
- FWCI
- 13.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal Cancer. https://app.cochat.ai/papers/10.1200/jco.2011.39.7901
- The paper
- Park, I. J., You, Y. N., Agarwal, A., Skibber, J. M., Rodriguez-Bigas, M. A., Eng, C., Feig, B. W., Das, P., Krishnan, S., Crane, C. H., Hu, C.-Y., & Chang, G. J. (2012). Neoadjuvant Treatment Response As an Early Response Indicator for Patients With Rectal Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.39.7901
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
